Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02594267 · ClinicalTrials.gov registry record · Phase 1
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02594267 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 48 participants.
The verdict
NCT02594267, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
Interventions
- DRUG Pralatrexate Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02594267
The ClinicalTrials.gov registry entry for NCT02594267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pralatrexate Injection is the first listed.
NCT02594267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02594267 about?
NCT02594267 is a clinical study titled "A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)". The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
What is the current status of trial NCT02594267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-11-10. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT02594267?
The interventions under investigation include: Pralatrexate Injection (DRUG).
Who is sponsoring clinical trial NCT02594267?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.